DURABLE IMPROVEMENTS IN URINARY INCONTINENCE AND POSITIVE TREATMENT RESPONSE IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME FOLLOWING LONG-TERM ONABOTULINUMTOXINA TREATMENT: FINAL RESULTS OF 3.5-YEAR STUDY

被引:0
|
作者
Khullar, V. [1 ]
Rechberger, T. [2 ]
Nitti, V. W. [3 ]
Radomski, S. [4 ]
De Ridder, D. [5 ]
Sussman, D. [6 ]
Sievert, K. [7 ]
Chapple, C. R. [8 ]
James, C. [9 ]
Zheng, Y. [10 ]
Sand, P. K. [11 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, London, England
[2] Med Univ, Dept Gynecol 2, Lublin, Poland
[3] NYU, New York, NY USA
[4] Univ Toronto, Toronto, ON, Canada
[5] Katholieke Univ Leuven, Univ Hosp, Leuven, Belgium
[6] Rowan Univ, Sch Osteopath Med, Stratford, NJ USA
[7] Univ Lubeck, Lubeck, Germany
[8] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England
[9] Allergan Ltd, Marlow, Bucks, England
[10] Allergan, Bridgewater, NJ USA
[11] Univ Chicago, Winnetka, IL USA
关键词
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
PP 11
引用
收藏
页码:S36 / S37
页数:2
相关论文
共 50 条
  • [31] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
    Paul K. Winner
    Andrew M. Blumenfeld
    Eric J. Eross
    Amelia C. Orejudos
    Debbie L. Mirjah
    Aubrey Manack Adams
    Mitchell F. Brin
    Drug Safety, 2019, 42 : 1013 - 1024
  • [32] Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
    Winner, Paul K.
    Blumenfeld, Andrew M.
    Eross, Eric J.
    Orejudos, Amelia C.
    Mirjah, Debbie L.
    Adams, Aubrey Manack
    Brin, Mitchell F.
    DRUG SAFETY, 2019, 42 (08) : 1013 - 1024
  • [33] LOW INCIDENCE OF CLEAN INTERMITTENT CATHETERISATION WITH ONABOTULINUMTOXINA IN DIVERSE AGE GROUPS OF OVERACTIVE BLADDER PATIENTS WITH CORRESPONDING IMPROVEMENTS IN URINARY SYMPTOMS, TREATMENT RESPONSE, AND QUALITY OF LIFE
    Nitti, V
    Drake, M.
    Everaert, K.
    Rovner, E.
    Dmochowski, R.
    Ginsberg, D.
    Radomski, S.
    Aboushwareb, T.
    Chang, C.
    Chapple, C.
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 : S300 - S301
  • [34] Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study
    Navarro-Perez, Maria Pilar
    Gonzalez-Quintanilla, Vicente
    Munoz-Vendrell, Albert
    Madrigal, Elisabet
    Alpuente, Alicia
    Latorre, German
    Molina, Francis
    Monzon, Maria Jose
    Medrano, Vicente
    Garcia-Azorin, David
    Gonzalez-Oria, Carmen
    Gago-Veiga, Ana
    Velasco, Fernando
    Beltran, Isabel
    Morollon, Noemi
    Viguera, Javier
    Casas-Limon, Javier
    Rodriguez-Vico, Jaime
    Cuadrado, Elisa
    Irimia, Pablo
    Iglesias, Fernando
    Guerrero-Peral, angel Luis
    Belvis, Robert
    Pozo-Rosich, Patricia
    Pascual, Julio
    Santos-Lasaosa, Sonia
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [35] EARLY AND CONSISTENT IMPROVEMENTS IN URINARY SYMPTOMS AND QUALITY OF LIFE IN IDIOPATHIC OVERACTIVE BLADDER PATIENTS FOLLOWING REPEAT TREATMENT WITH ONABOTULINUMTOXINA: RESULTS OF A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 4 TRIAL
    McCammon, K.
    Gousse, A.
    Gruenenfelder, J.
    Hale, D.
    Orejudos, A.
    Patel, A.
    Kahan, A.
    NEUROUROLOGY AND URODYNAMICS, 2018, 37 : S395 - S396
  • [36] Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome
    Haab, F
    Cardozo, L
    Chapple, C
    Ridder, AM
    EUROPEAN UROLOGY, 2005, 47 (03) : 376 - 384
  • [37] Long-term persistence and compliance with darifenacin treatment for overactive bladder: results of a 2-year open-label extension study.
    Hill, S
    Lheritier, K
    Kawakami, F
    PHARMACOTHERAPY, 2005, 25 (10): : 1493 - 1493
  • [38] LONG-TERM EFFICACY AND SAFETY OF URO-902 (PVAX/HSLO) IN WOMEN WITH OVERACTIVE BLADDER AND URGE URINARY INCONTINENCE: FINAL RESULTS OF A PHASE 2A TRIAL
    Peters, Kenneth M.
    Enemchukwu, Ekene A.
    Kalota, Susan
    Robertson, Kaiser
    Ge, Sijian
    Lu, Jingmei
    Badger, Hanh
    Mujais, Salim
    JOURNAL OF UROLOGY, 2023, 209 : E1184 - E1184
  • [40] EARLY ONSET AND CONSISTENT RESPONSE OF ONABOTULINUMTOXINA TREATMENT WITH SIGNIFICANT RESOLUTION OF URINARY SYMPTOMS IN FEMALE OVERACTIVE BLADDER PATIENTS WITH URINARY INCONTINENCE IN A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 4 TRIAL
    Mccammon, K.
    Gruenenfelder, J.
    Lucente, V. R.
    Orejudos, A.
    Aboushwareb, T.
    Hale, D. S.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2017, 28 : S19 - S20